Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
The mutant prevention concentrations (MPCs) of levofloxacin alone and in combination with ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin were established against Pseudomonas aeruginosa. Antibiotic combinations using levofloxacin with any antibiotic with individual activity against P. aeruginosa resulted in synergistic lowering (an at-least-fourfold reduction) of the isolate's MPC.
Zhanel
George G
GG
Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada. ggzhanel@pcs.mb.ca
Mayer
Matthew
M
Laing
Nancy
N
Adam
Heather J
HJ
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D066298:In Vitro Techniques; D064704:Levofloxacin; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000187:drug effects*; D015242:Ofloxacin / Q000494:pharmacology; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D000077725:Piperacillin, Tazobactam Drug Combination; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000235:genetics*; D013845:Thienamycins / Q000494:pharmacology; D014031:Tobramycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077725:Piperacillin, Tazobactam Drug Combination; D064704:Levofloxacin; D017963:Azithromycin; D010397:Penicillanic Acid; D002442:Ceftazidime; D015242:Ofloxacin; D000077731:Meropenem; D014031:Tobramycin; D010878:Piperacillin; D003091:Colistin